相关实验视频
Updated: May 27, 2025
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.0K
β-基-β-甲基酸盐 (HMB) 通过抑制巨细胞中ERK/NF-κB激活来改善DSS诱导的大肠炎
概括
在小鼠炎症性肠病 (IBD) 模型中,β-Hydroxy β-Methylbutyrate (HMB) 显示出显著的抗炎作用. 这项研究表明,HMB可以减轻结肠损伤并减少关键的炎症标志物,这表明它对IBD的治疗潜力.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- β-基β-甲基酸盐 (HMB) 是一种氨酸代谢物,因其抗氧化和抗炎性质而闻名.
- 在治疗炎症性肠病 (IBD) 中HMB的治疗潜力仍然不完全理解,需要进一步调查.
研究的目的:
- 在小鼠模型中研究HMB对酸硫酸盐 (DSS) 诱导的慢性结肠炎的治疗作用.
- 阐明HMB在结肠炎中发挥抗炎作用的潜在分子机制.
主要方法:
- 使用DSS诱导建立了慢性结肠炎的小鼠模型,并监测了体重,结肠长度,疾病活动指数 (DAI) 和粗病理学.
- 免疫组织化学,流细胞测量和定量聚合酶链反应 (qPCR) 用于评估结肠组织和巨标记物,包括奥克卢丁,F4/80,CD80,CD86和各种细胞因子 (IL-6,IL-1β,TNF-α,IL-22,CXCL2,iNOS).
- 骨髓衍生的树突性巨细胞 (BMDMs) 的RNA测序和p-ERK和p-p65酸化的西部斑点分析进行了以探索机械途径.
主要成果:
- 在小鼠中,HMB治疗显著改善了DSS诱导的结肠损伤,并减少了疾病活性.
- 在结肠组织中,HMB的使用上调了奥克卢丁的表达,并降低了关键的促炎细胞因子 (IL-6,IL-1β,TNF-α,CXCL2) 的调节.
- 在体外研究证实了HMB通过抑制ERK和p65酸化来降低DSS诱导的细胞因子产生和抑制巨细胞激活标志物 (CD80,CD86) 的能力.
结论:
- HMB对肠道炎症表现出显著的抗炎性质,将其定位为IBD的有希望的治疗候选者.
- 据证明,HMB能够保持肌肉质量并减少全身炎症,这表明它有可能作为IBD的辅助疗法.
- 将HMB与常规抗炎疗法结合使用可能为复杂IBD病例患者提供更好的治疗结果.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:17Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
01:29Inflammatory Bowel Disease IV: Pharmacological Management
89
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
89